Pharmaceutical

AstraZeneca buys Chinese CAR-T biotech Gracell in a $1.2bn deal

The deal is worth approximately $1.2bn in combined upfront and potential contingent value payments and is expected to close in Q1 2024.

Dec 28, 2023 - 18:00
AstraZeneca buys Chinese CAR-T biotech Gracell in a $1.2bn deal
The deal is worth approximately $1.2bn in combined upfront and potential contingent value payments and is expected to close in Q1 2024.
Read the original article

Tags:

Previous Article

ARTBIO divulges plans for proprietary isotope manufacturing technology

Next Article

Bristol Myers Squibb agrees to acquire RPT company RayzeBio for $4.1bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CervoMed’s stock rises as FDA grants orphan drug status to dementia drug

CervoMed’s stock rises as FDA grants orphan drug status...

Nov 29, 2024

Pivotal bioVenture raises the stakes in biotech and pharmaceutical support

Pivotal bioVenture raises the stakes in biotech and pha...

Dec 18, 2023

WHO says aspartame might cause cancer — but that most adult consumers don’t need to worry

WHO says aspartame might cause cancer — but that most a...

Jul 14, 2023